Venous access in haemophilic children: choice and management
- PMID: 20059565
- DOI: 10.1111/j.1365-2516.2009.02156.x
Venous access in haemophilic children: choice and management
Abstract
Current haemophilia treatment in children is based on regular intravenous infusions of concentrates for prolonged periods, according to prophylaxis regimens or immune tolerance induction treatment, in cases of inhibitor development. Therefore, a stable and uncomplicated venous access is required and as such peripheral veins represent the preferred option. However, frequent infusions in the home setting can be problematic in very young children and for this reason, central venous access devices (CVADs) have been widely used to improve treatment feasibility. Unfortunately CVADs' use is associated with a high rate of complications, and infections and thrombotic occlusion can influence treatment outcome by causing unwanted treatment interruption. CVADs can be grouped into three main categories: external non-tunnelled, external tunnelled and fully implantable devices known as ports. The management of CVADs at home often represents a challenge because a strict adherence to sterile procedures is required. Indeed, the incidence of infections with ports is much lower than that reported for external devices; however, ports carry the inconvenience of needle sticks. More recently, arteriovenous fistula was shown to be a suitable alternative to CVADs because it is easy to use and is associated with a lower rate of complication.
Similar articles
-
The use of central venous catheters in haemophilia patients.Haemophilia. 2010 Jan;16 Suppl 1:29-31. doi: 10.1111/j.1365-2516.2009.02157.x. Haemophilia. 2010. PMID: 20059567 Review.
-
Feasibility of prophylaxis and immune tolerance induction regimens in haemophilic children using fully implantable central venous catheters.Br J Haematol. 2008 May;141(5):689-95. doi: 10.1111/j.1365-2141.2008.07087.x. Epub 2008 Apr 10. Br J Haematol. 2008. PMID: 18410458
-
Overview of the use of implantable venous access devices in the management of children with inherited bleeding disorders.Haemophilia. 2006 Dec;12 Suppl 6:87-93. doi: 10.1111/j.1365-2516.2006.01371.x. Haemophilia. 2006. PMID: 17123400 Review.
-
Consensus recommendations for use of central venous access devices in haemophilia.Haemophilia. 2004 Sep;10(5):629-48. doi: 10.1111/j.1365-2516.2004.00943.x. Haemophilia. 2004. PMID: 15357790 Review.
-
Barriers to primary prophylaxis in haemophilic children: the issue of the venous access.Blood Transfus. 2008 Sep;6 Suppl 2(Suppl 2):s12-6. doi: 10.2450/2008.0031-08. Blood Transfus. 2008. PMID: 19105504 Free PMC article. Review.
Cited by
-
Past, present and future of hemophilia: a narrative review.Orphanet J Rare Dis. 2012 May 2;7:24. doi: 10.1186/1750-1172-7-24. Orphanet J Rare Dis. 2012. PMID: 22551339 Free PMC article. Review.
-
Issues in pediatric haemophilia care.Ital J Pediatr. 2013 Apr 20;39:24. doi: 10.1186/1824-7288-39-24. Ital J Pediatr. 2013. PMID: 23601343 Free PMC article. Review.
-
Concizumab prophylaxis in people with hemophilia A or B without inhibitors: patient-reported outcome results from the phase 3 explorer8 study.Res Pract Thromb Haemost. 2025 Feb 20;9(2):102705. doi: 10.1016/j.rpth.2025.102705. eCollection 2025 Feb. Res Pract Thromb Haemost. 2025. PMID: 40166710 Free PMC article.
-
Gene therapy for haemophilia.Cochrane Database Syst Rev. 2020 Apr 28;4(4):CD010822. doi: 10.1002/14651858.CD010822.pub4. Cochrane Database Syst Rev. 2020. PMID: 32342499 Free PMC article.
-
Practical aspects of extended half-life products for the treatment of haemophilia.Ther Adv Hematol. 2018 Sep 6;9(9):295-308. doi: 10.1177/2040620718796429. eCollection 2018 Sep. Ther Adv Hematol. 2018. PMID: 30210757 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical